Clinical Trials Browser

INDUSTRY × Neoplasms × tovorafenib × Clear all

NCT05760586 2024-08-12

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Approved for marketing

Glioma, Neoplasms

NCT01425008 2020-08-10

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Phase 1 Completed

149 enrolled 43 charts

Melanoma, Neoplasms